In a ruling cited in its July Bulletin, the PMPRB also found that ICN Canada had been selling ribavirin "at an excessive price" since January 1994. Exercising its remedial power to the full extent permitted by the Patent Act, the PMPRB ordered the company to reduce the price from $1540 to about $200, which is less than the 1996 maximum nonexcessive price of $400. It also ordered the company to pay the federal government $1.2 million -- the board estimate of total excess revenues earned by ICN Canada.